Galenica
Corporate brand
UnclaimedSwiss healthcare group combining pharmaceutical activities, pharmacy retail, healthcare information services and pharmaceutical logistics.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Galenica is a Swiss healthcare group headquartered in Bern and listed on the SIX Swiss Exchange under the ticker GALN. The company combines pharmaceutical activities with pharmacy retail, healthcare information services and the distribution and logistics of medicines and other healthcare products. Its name refers to Galenus, the ancient physician whose work influenced the development of Western medical knowledge. The business originated as a cooperative purchasing initiative among Swiss pharmacists. The historical record associated with Galenica describes the founding of a purchasing centre by 16 pharmacists in the French-speaking part of Switzerland, followed by the adoption of the Galenica name in the early twentieth century and a move to Bern. Some published accounts give an 1827 founding date, while the company’s commonly cited corporate history places the origin in 1927 through Collaboration Pharmaceutique SA. Because of this inconsistency, 1927 is used here as the organizational founding year, with the earlier date treated as unresolved. Galenica initially focused on collective purchasing and supply for pharmacies. It broadened its role during the mid-twentieth century by establishing scientific documentation capabilities, acquiring pharmaceutical businesses and developing promotional and distribution services for parapharmaceutical products. Its acquisition of Panpharma in 1957 marked an important step into pharmaceutical activities. During the 1970s, further acquisitions supported the development and production of over-the-counter medicines. In 1983, the purchase of Hausmann AG laboratories added products for iron deficiency, later associated with the Venofer and Maltofer brands. Information management became a significant part of the group. Galenica created Documentation Galenica in 1938 and later established e-mediat in 2001 to provide healthcare databases and information services. Its publishing subsidiary Documed became known for the Swiss drug compendium, a reference work containing official medicine information. These activities placed Galenica at the intersection of pharmaceutical data, prescribing information, pharmacy operations and healthcare administration. The group also expanded into pharmacy retail. GaleniCare was founded in 2000 and became the platform for pharmacy-chain activities including Amavita and Sun Store. Galenica participates in Coop Vitality Pharmacy, a joint venture with Coop. Its logistics network includes Galexis and Alloga, which supply pharmacies, hospitals and other healthcare customers. This combination of retail, distribution, information and pharmaceutical products gives Galenica an integrated position in the Swiss healthcare market. From the late 1990s through the 2010s, Galenica underwent major ownership and structural changes. Alliance Boots acquired a minority holding in 1999. That interest subsequently passed through ownership involving KKR and Stefano Pessina and later Walgreens Boots Alliance-related structures. In 2014, Galenica was organized around the Vifor Pharma and Galenica Santé divisions, with the stated objective of separating the businesses. Galenica Santé became an independent publicly traded company in April 2017, while the pharmaceutical business continued under the Vifor Pharma identity. The group acquired Canadian biotechnology company Aspreva Pharmaceuticals in 2008, creating a foundation for a more internationally oriented, specialized pharmaceutical business. In 2016, the pharmaceutical division agreed to acquire US biotechnology company Relypsa for more than US$1.5 billion, a transaction associated with the separation of the pharmaceutical and healthcare-services operations. Galenica subsequently strengthened its patient-focused offering in Switzerland, including a majority investment in the Berner-Bichsel Group in 2019. Berner-Bichsel specializes in personalized medicines and homecare services. Today, Galenica’s business identity is primarily Swiss and healthcare focused. Its activities span pharmacy retail, pharmaceutical distribution, logistics, healthcare data and information services, consumer and prescription-related products, and patient-oriented services. The company’s competitive proposition rests on operating infrastructure embedded in the Swiss medicine-supply chain rather than on a single consumer product brand. The Galenica name therefore functions chiefly as a corporate and healthcare-services brand, while many customer-facing activities are delivered through subsidiaries and partner brands.
History
Galenica developed from a cooperative purchasing model created by Swiss pharmacists. The organization is commonly traced to Collaboration Pharmaceutique SA, established in 1927 by 16 pharmacists in Clarens, although some accounts state an 1827 origin. The enterprise adopted the Galenica name in 1932 and moved from the canton of Vaud to Bern. Its original purpose was to improve purchasing and supply conditions for pharmacies through collective organization. In 1938, Galenica established a scientific documentation service, laying an early foundation for its later healthcare-information activities. From 1957 onward, it diversified through acquisitions and subsidiaries. The acquisition of Panpharma AG that year expanded the group into pharmaceutical activities and the promotion of parapharmaceutical products for pharmacies. Additional acquisitions during the 1970s helped Galenica develop and produce over-the-counter medicines. In 1977, it published the Codex Galenica, described as the first comprehensive list of medicines in Switzerland. The 1983 acquisition of Hausmann AG laboratories strengthened its pharmaceutical portfolio, including iron-deficiency products later marketed as Venofer and Maltofer. Galenica expanded its information and publishing infrastructure through Documed, founded in 1976, and e-mediat, established in 2001. Documed published the Swiss Arzneimittelkompendium drug compendium from 1978. Because Swissmedic required pharmaceutical companies to publish medicine information in the compendium, Documed’s position attracted criticism. A dispute later arose over access to medicine information and the creation of the open-data database oddb.org. The Swiss Federal Administrative Court supported the open-access position, after which Swissmedic developed the AIPS platform for free public access to official medicine information. Documed subsequently won a tender to build and operate that platform. In 2000, Galenica founded GaleniCare, creating the basis for a pharmacy-retail division. The group later operated or participated in pharmacy chains and partnerships including Amavita, Sun Store and Coop Vitality Pharmacy. Its other Swiss healthcare infrastructure includes Galexis and Alloga, which distribute medicines and healthcare goods to pharmacies, hospitals and other customers. The company entered a strategic relationship with Alliance Boots in 1999 when Alliance Boots acquired 25 percent of Galenica’s shares. The stake later became associated with ownership involving KKR and Stefano Pessina after the 2007 takeover of Alliance Boots, and with Walgreens Boots Alliance-related structures after the 2014 Walgreens transaction. These changes did not prevent Galenica from continuing its own strategic development. Galenica’s pharmaceutical ambitions grew substantially through the acquisition of Aspreva Pharmaceuticals in 2008. The transaction supported the formation of a globally active, specialized pharmaceutical operation under the Vifor Pharma name. In August 2014, the group was divided into the Vifor Pharma and Galenica Santé divisions, with a longer-term plan to establish two independent companies. The separation culminated in the independent stock-market listing of Galenica Santé, subsequently operating as Galenica, on 7 April 2017. The pharmaceutical business remained separate under Vifor Pharma. As part of the separation strategy, Galenica acquired Relypsa, a US biotechnology company, in 2016 for a reported price above US$1.5 billion. The transaction was intended to reinforce the specialized pharmaceutical business. In 2019, the Swiss group acquired a majority stake in Berner-Bichsel, whose activities include personalized medicines and homecare for patients. Galenica’s current corporate identity reflects the healthcare-services side of the former group. It combines pharmacy retail, distribution, logistics, information systems and patient services, while maintaining pharmaceutical and consumer-healthcare activities through subsidiaries and associated businesses. Its historical evolution has therefore been from a pharmacist purchasing cooperative into an integrated healthcare platform with a particularly strong position in Switzerland.
- 2019
Majority stake in Berner-Bichsel Group
[1]Galenica expands into personalized medicines and patient homecare through a majority investment in Berner-Bichsel.
- 2017
Galenica becomes independently listed
[1]The healthcare-services business becomes an independent company listed on the SIX Swiss Exchange on 7 April.
- 2016
Relypsa is acquired
[1]Galenica agrees to acquire the US biotechnology company Relypsa for more than US$1.5 billion.
- 2014
The group is divided into two divisions
[1]Galenica organizes its activities into Vifor Pharma and Galenica Santé as a step toward a future corporate separation.
- 2008
Aspreva Pharmaceuticals is acquired
[1]The Canadian pharmaceutical company is acquired, supporting the development of the internationally oriented Vifor Pharma business.
- 2001
e-mediat is established
[1]Information-processing activities are transferred to a new Bern-based healthcare-information company.
- 2000
GaleniCare is founded
[1]The new company becomes the platform for Galenica’s pharmacy-chain operations.
- 1999
Alliance Boots takes a minority stake
[1]Alliance Boots acquires 25 percent of Galenica’s shares as part of a strategic partnership.
- 1983
Hausmann AG laboratories are acquired
[1]The acquisition expands Galenica’s pharmaceutical manufacturing and iron-deficiency treatment activities.
- 1977
Codex Galenica is published
[1]Galenica publishes a comprehensive Swiss medicine directory in book form.
Products and positioning
Integrated Swiss healthcare and pharmaceutical-services provider linking pharmacies, pharmaceutical distribution, healthcare information, logistics and patient-oriented services.
Iron-deficiency treatment
Venofer
Venofer is an iron-deficiency treatment associated with the Hausmann laboratories business acquired by Galenica in 1983. It represents the group’s historical role in developing and marketing specialized pharmaceutical products rather than only distributing medicines. The product became one of the recognizable pharmaceutical brands connected with Galenica’s former and associated pharmaceutical operations.
Iron-deficiency treatment
Maltofer
Maltofer is an iron-deficiency product originating from the pharmaceutical activities expanded through the acquisition of Hausmann AG laboratories. It illustrates Galenica’s move from cooperative purchasing and distribution into the development, production and marketing of medicines for defined therapeutic needs.
Pharmacy retail
Amavita
Amavita is one of Galenica’s Swiss pharmacy chains. The network provides prescription medicines, consumer healthcare products, pharmacy advice and patient-oriented services. It is part of the retail infrastructure established through GaleniCare and is a principal customer-facing expression of Galenica’s healthcare-services business.
Pharmacy retail
Sun Store
Sun Store is a Swiss pharmacy chain within Galenica’s retail activities. Its stores combine medicine dispensing with consumer-healthcare and pharmacy services, complementing the Amavita network and extending Galenica’s direct presence in the Swiss healthcare market.
Pharmacy retail joint venture
Coop Vitality Pharmacy
Coop Vitality Pharmacy is a pharmacy business operated through cooperation between Galenica and Swiss retailer Coop. The partnership combines Galenica’s pharmacy and healthcare expertise with Coop’s retail footprint and customer reach.
Pharmaceutical distribution
Galexis
Galexis is a Galenica logistics and distribution company serving the Swiss healthcare supply chain. Its activities support the movement of medicines and healthcare products to pharmacies, hospitals and other professional customers.
Healthcare logistics
Alloga
Alloga provides pharmaceutical and healthcare logistics within Galenica’s distribution infrastructure. It supports storage, handling and supply-chain services for healthcare manufacturers and professional customers.
Controversies
2012
Competition investigation over pharmaceutical-information databases
The Swiss Competition Commission opened proceedings involving Galenica subsidiaries Documed, e-mediat and HCI Solutions. The investigation concerned alleged abuse of a dominant position in medicine-information databases, including claims that companies were charged for access to pharmaceutical data and that smaller manufacturers faced threats of removal from systems used by hospitals and other institutions. The dispute also involved the development of alternative and open-access information platforms.
Brand decisions
2019
Acquire majority stake in Berner-Bichsel GroupM&ABackground
Galenica aimed to broaden patient-oriented services beyond conventional pharmacy retail and distribution.
Action taken
The company acquired a majority stake in Berner-Bichsel Group.
Aftermath
Galenica expanded its activities in personalized medicines and patient homecare.
2016
Acquire RelypsaM&ABackground
The planned separation of Galenica’s businesses required continued investment in the specialized pharmaceutical operation.
Action taken
Galenica agreed to acquire US biotechnology company Relypsa for more than US$1.5 billion.
Aftermath
The acquisition strengthened the pharmaceutical side of the group before the healthcare-services business became independently listed.
Reported acquisition value. More than US$1.5 billion (2016)
2014
Separate the Vifor Pharma and Galenica Santé businessesStrategyBackground
Galenica had developed two substantially different operating areas: an internationally oriented pharmaceutical business and a Swiss healthcare-services business spanning retail, distribution and information activities.
Action taken
The group reorganized its activities into the Vifor Pharma and Galenica Santé divisions and pursued the creation of two independent companies.
Aftermath
The separation culminated in the independent listing of Galenica Santé in April 2017, while Vifor Pharma continued as the separate pharmaceutical business.
2008
Acquire Aspreva PharmaceuticalsM&ABackground
Galenica sought to build a specialized pharmaceutical business with international reach.
Action taken
The company acquired Canadian pharmaceutical company Aspreva Pharmaceuticals.
Aftermath
The transaction contributed to the formation and expansion of the Vifor Pharma platform.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/galenica · Editorial policy · How profiles are compiled